Celerion Adds Containment Room
Modular containment room at Belfast facility allows studies of biologics and vaccines.
RELATED ARTICLES
Celerion added a containment room at the Belfast, Northern Ireland, UK facility, the company announced in a press release. The new containment room will allow Celerion to develop programs that require studies utilizing biologics, as well as vaccines with primary and secondary containment.
The modular facility uses a negative-pressure processing room that houses a Biosafety Level (BSL-2) cabinet. The room enables processing of live class 2 and class 3 biological products.
Celerion’s facility in Belfast also has extensive early-stage clinical capabilities based on First-In-Human experience with both NCEs and biologics, as well as bioequivalence, biosimilars, obesity, ophthalmic, and gastro-intestinal studies.
Texas' MD Anderson Cancer Center Creates New Cell Therapy Institute
November 11th 2024With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.
